Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies

Effects of nicotine withdrawal on cognition in a clinical trial setting

(2013) Keith A. Wesnes et al.   PSYCHOPHARMACOLOGY

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

(2011) Bruce J. Kinon et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

mGlu2 Metabotropic Glutamate Receptors Restrain Inflammatory Pain and Mediate the Analgesic Activity of Dual mGlu2/mGlu3 Receptor Agonists

(2011) Magda Zammataro et al.   Molecular Pain

Ketamine effects on brain function — Simultaneous fMRI/EEG during a visual oddball task

(2011) Francesco Musso et al.   NEUROIMAGE

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

(2011) Matthew J. Fell et al.   NEUROPHARMACOLOGY

Group II metabotropic glutamate receptors (mGlu2/3) in drug addiction

(2010) Khaled Moussawi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition

(2008) Guibao Gu et al.   BRAIN RESEARCH